Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target
Benzinga Newsdesk 4 months ago
NewsPrice TargetReiterationAnalyst Ratings
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $31 price target.
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $31 price target.